



Universiteit  
Leiden

The Netherlands

## How negative experiences influence the brain in pain: neuroimaging and biobehavioral insights

Thomaidou, A.M.

### Citation

Thomaidou, A. M. (2022, September 7). *How negative experiences influence the brain in pain: neuroimaging and biobehavioral insights*. Retrieved from <https://hdl.handle.net/1887/3455208>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3455208>

**Note:** To cite this publication please use the final published version (if applicable).

# Chapter 6.

*Temporal structure of brain oscillations predicts learned nocebo responses to pain.*

**Published as**

Thomaidou MA, Blythe JS, Houtman S, Veldhuijzen DS, van Laarhoven AIM, Evers AWM. Temporal structure of brain oscillations predicts learned nocebo responses to pain. *Scientific Reports* 11(1):9807, May 2021.

## *Abstract*

This study aimed to identify electrophysiological biomarkers of nocebo-augmented pain. Nocebo hyperalgesia (i.e., increases in perceived pain resulting from negative expectations) was induced in 36 healthy participants through classical conditioning and negative suggestions. In a baseline phase, participants received high thermal pain stimulations. During acquisition, participants learned to associate an inert gel applied to their forearm with high pain, relative to a moderate intensity control stimulus administered without gel. During evocation, nocebo and control stimuli were both accompanied by moderate pain to measure nocebo responses. Electroencephalography was recorded during rest (pre and post nocebo acquisition) and during pain stimulation (baseline, nocebo acquisition and evocation). Nocebo hyperalgesia led to pre- to post-acquisition increases in long-range temporal correlations (LRTC), with beta-band alterations being negatively associated with nocebo magnitudes. Moreover, individuals with strong LRTC at rest showed larger nocebo responses than those with weaker LRTC. Nocebo acquisition trials showed reduced alpha power. Alpha power was higher while LRTC were lower during nocebo-augmented pain, compared to baseline. By involving LRTC, these findings support nocebo learning theories and highlight a role of nocebo-induced cognitive processing. This study provides novel insights into neural underpinnings of nocebo hyperalgesia, a phenomenon that greatly impacts the experience of pain.

## ***Introduction***

The experience of pain varies widely between and within individuals and can be shaped by cognitive processes such as learning. Nocebo hyperalgesia, a worsening in perceived pain attributed to negative expectations, demonstrates that learning can be detrimental for the experience of pain<sup>1–3</sup>. Memories and negative expectations may directly impact pain processing<sup>4,5</sup>, yet it remains unclear which specific processes are involved in cognitive pain reappraisal and how negative expectations may shape physiological characteristics of pain.

Electroencephalography (EEG) can be used to identify physiological markers of phenomena that include cognitive components<sup>6,7</sup> such as nocebo effects. EEG has been used in cognitive and pain research and has largely focused on spectral characteristics of brain oscillations, with evidence indicating that expectations<sup>8,9</sup> and cognitive pain regulation<sup>10,11</sup> are reflected through alterations in the alpha and beta power bands. Concurrently, EEG research has shown that gamma oscillations are involved in associative learning<sup>12</sup> and encoding of ongoing pain<sup>13</sup>. Alpha and gamma oscillations may also act in synergy during the cognitive stages of nociceptive processing<sup>14</sup>. How EEG measures within these frequency bands relate to pain and cognitive processing under hyperalgesic conditions remains unclear.

Electrophysiological research into nocebo effects has been scarce and has mainly focused on the power spectrum of oscillations<sup>15–19</sup>. However, in order to more precisely pinpoint cognitive processes involved in nocebo, it may be valuable to utilize sophisticated EEG biomarkers such as Detrended Fluctuation Analysis (DFA), a component that quantifies long-range temporal correlations (LRTC) between oscillating groups of neurons and determines how oscillation

amplitudes change over time<sup>20</sup>. Higher LRTC generally indicate higher complexity of neural activity and have accordingly been shown to play a role in cognitive processes such as attention and cognitive reappraisal<sup>20–22</sup>. Decreases in LRTC of oscillations have been found in schizophrenia<sup>23</sup> and Alzheimer's disease<sup>24</sup>, with both disorders being characterized by cognitive deficiencies. Moreover, strong LRTC of beta and gamma oscillations have been associated with poor sustained attention performance<sup>25</sup>. Despite its evident and intricate relationship to cognitive processing, complexity of brain activity has never been tested under nocebo hyperalgesic conditions.

As described, we based this study on earlier findings relating to changes in (resting-state) oscillatory power in the alpha band. Additionally, we aimed to explore nocebo correlates relating specifically to LRTC of brain oscillations during active pain states throughout the experiment. We expected that the magnitude of induced nocebo hyperalgesia would be positively correlated to pre- to post-acquisition LRTC alterations in the alpha band, while we expected the opposite relationship in the beta and gamma bands. Furthermore, we expected that the experience of control versus nocebo trials during the acquisition and evocation phases would be characterized by divergent EEG biomarker values. Additionally, we expected that the experience of nocebo-augmented pain and baseline high-pain stimulations would be characterized by divergent EEG biomarker values. Finally, we explored the relationship between pain-related psychological characteristics and measures of EEG.

## *Materials and methods*

### *Participants*

Participants of either sex were enrolled in this study. The required sample size for the primary analysis was calculated based on a previous nocebo study<sup>18</sup> that induced nocebo hyperalgesia on thermal pain by use of conditioning, in an MEG paradigm. This study was used merely as an indicator of an appropriate sample size for this comparable study, in lack of a more fitting study to base a power analysis on. Tu et al. (2019) found that a decrease in alpha band connectivity predicted the magnitude of conditioned nocebo hyperalgesia ( $r = 0.46, p = 0.04$ ). The power analysis was conducted in G\*power 3.1<sup>26</sup> for our primary hypothesis. Alpha error probability was set at  $\alpha = 0.05$ , and desired power was set at 0.80. With  $r$  of 0.46, the sample size indicated was 36 participants. A replacement protocol was used for excluded participants.

Inclusion criteria were: age between 18 and 35 years, a good understanding of the English language, and (corrected to) normal vision and hearing. Exclusion criteria were pregnancy or breastfeeding, any pain on the day of testing, having recent injuries on the arms, painful health conditions experienced in the past 6 months, ever having experienced chronic medical or psychiatric conditions, and having consumed psychotropic or analgesic medication, recreational drugs, or more than 3 units of alcohol, in the 24 hours prior to the study appointment. Testing of included participants was discontinued in the case that they would be determined to have too high of a pain threshold (i.e., when thermode maximum temperatures were not sufficient to induce at least moderate pain) or when they would not reliably report a difference (a mean of at least 1.5 on the NRS) between the administered temperatures for control and nocebo trials in the acquisition phase. Participants were recruited through the online website Sona (Sona Systems, Tallinn, Estonia). Study participation involved a 3-hour

recording session at a laboratory of the Faculty of Social and Behavioral Sciences of Leiden University, the Netherlands. All participants provided written informed consent prior to participation. After completing the experiment, all participants were reimbursed by either study credits or cash. The study was approved by the Leiden University Psychology Research Ethics Committee (CEP19-1031/532; all methods and procedures were performed in accordance with the relevant guidelines and regulations) and pre-registered on ClinicalTrials.gov (NCT04199858, 16/12/2019; planned analyses of frequency biomarkers were not conducted due to the scope of this paper).

### ***Experimental design***

This study utilized a within-subjects design. All participants underwent 1) a calibration phase, 2) a baseline phase, and a nocebo phase comprising 3) nocebo acquisition and 4) nocebo evocation (**Fig. 1a**). During the first phase, calibrations for warmth and pain perception were conducted. During the baseline phase, moderate- and high-pain stimuli were administered. During nocebo acquisition, a conditioning procedure took place, in which associations were learned between the nocebo treatment and higher pain. Participants were conditioned to associate a sham pain-increasing gel with high (increased) pain stimulations, and no gel (control) with moderate-pain stimulations. During nocebo evocation, these learned associations were tested.

### ***Thermal pain application***

Thermal pain stimuli were delivered to the volar forearm using a Thermal Sensory Analyzer with a 3×3 cm ATS thermode probe (TSA-

II; Medoc Advanced Medical Systems, Ramat Yishai, Israel). During the calibrations and baseline phases, both arms were used for pain stimulations. During the placebo phase, only the right arm was used (**Fig. 1b**). Throughout the experiment, pain intensities were rated on a numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable in this context).

### *Sensory and pain thresholds*

Before the start of the experimental phases, warmth and pain threshold levels were tested for each participant, heat stimuli were applied and participants were asked to indicate the first moment at which they perceived warmth and pain. After a practice trial for each, the average of 3 warmth detection values and 3 heat pain detection values determined the thresholds for warmth and pain, respectively. This method follows published standardized procedures <sup>27</sup>.

### *Pain calibration protocol*

Pain calibrations were conducted in order to determine the temperatures that would induce moderate and high pain during baseline and placebo phases. The calibrations were individually tailored, based on the NRS ratings of 16 heat stimuli of varying intensities. Throughout the experiment, each pain stimulus was initiated from a 32°C baseline, increased to a target temperature, and presented for 10 seconds at plateau. The ramp up and return rates were 8°C per second. During calibrations the inter-stimulus interval (ISI) was 5 seconds, during which NRS pain ratings were given. Median temperatures rated as NRS 3 to 5

were used to induce moderate pain and median temperatures rated as NRS 6 to 8 were used to induce high pain.

### *Baseline, acquisition, and evocation phases*

During baseline, 2 moderate and 6 high pain trials were administered on both arms, with an ISI of 5 seconds. During acquisition, 16 nocebo and 16 control stimuli were administered in alternating order. During evocation, 8 nocebo and 8 control stimuli were administered in alternating order. During nocebo acquisition and evocation, the ISI was 10 seconds. In all phases the thermode was moved to a more proximal site on the arm after each pain trial, in order to avoid habituation or sensitization to heat-pain.

### *Nocebo manipulation*

A commercial moisturizing gel that was given the name “Trans-Dermal Aspartate” or “TDA” was used as the nocebo treatment in the procedure; participants were told it was a capsaicin gel used on the skin for research purposes only. Half of the participants received the gel from a blue jar and the other half from a brown jar, both featuring sham pharmaceutical labels. Negative suggestions were used to create expectations regarding the pain enhancing effects of the gel. Participants were told that the gel is a capsaicin-based gel that is known for its pain-increasing properties. Participants’ arms were marked with medical tape to create four 3x3 cm thermode-placement sites on both arms. Prior to the start of the acquisition phase, the gel was rubbed into the two nocebo sites (the first and third most proximal sites on the right arm). Messages displayed on a computer screen via E-Prime 2.0 (Psychology Software

Tools, Pittsburgh, PA, USA) indicated whether a trial was on a gel site or on a control site. The messages read “Trans-Dermal Aspartate, pain-increasing capsaicin, gel form” or “Control trial, no gel”.

During nocebo acquisition, the nocebo gel was paired to surreptitiously increased pain stimulations during nocebo trials, while moderate pain was delivered during control trials. During nocebo evocation, all pain stimuli during both nocebo and control trials were applied at moderate intensity, to study whether evoked conditioned responses were elicited. Increased pain reports for a nocebo trial as compared to its preceding control trial in this phase indicated nocebo hyperalgesia.

### ***EEG materials***

EEG recordings were conducted using the ActiveTwo BioSemi (Amsterdam, the Netherlands) electrode system from 32 scalp electrodes. As reference electrodes, BioSemi replaces the ground electrodes that are used in conventional systems with two additional electrodes. The Common Mode Sense active electrode and Driven Right Leg passive electrode form a feedback loop, which drives the average potential of the participant as close as possible to the reference voltage of the analog-to-digital converter, thus rendering them references. Data was acquired at a sampling rate of 1024 Hz, band-passed filtered online during acquisition from 0.1 to 100 Hz (with a 100 Hz low-pass and 0.01 Hz high-pass hardware filter). Electrodes were placed on the scalp according to the international 10–20 system and where possible, electrode impedances were kept below 20 kOhm.

### ***Questionnaires***

Three questionnaires were used to measure baseline differences in psychological characteristics. The questionnaires were completed by participants prior to their lab visit. Total scores were used for the following questionnaires: The Pain Catastrophizing Scale (PCS; Sullivan, Bishop, and Pivik, 1995), the Fear of Pain Questionnaire (FPQ-III; McNeil and Rainwater, 1998), and the Experience of Cognitive intrusions on Pain scale (ECIP; Attridge et al., 2015). At the end of the experiment, participants also completed an exit questionnaire containing manipulation check questions, assessing, for example, whether participants understood the instructions. All questionnaires, as well as a debriefing form, were displayed via web-based survey software (Qualtrics, Provo, Utah, USA).

### *Experimental procedure*

Before the day of testing, participants completed a brief online screening as well as the psychological questionnaires. On the day of the testing session, participants received further information about the procedures and provided written informed consent. Then, participants completed a brief screening for inclusion and were provided with information about the EEG and the (sham) pain-enhancing effects of the placebo gel. EEG caps were then mounted, electrolyte gel was applied (SignaGel, Parker laboratories Inc., Fairfield, New Jersey, USA) and the scalp electrodes were placed. Warmth and pain threshold levels were then tested and individual pain stimuli were calibrated. Thereafter, continuous EEG recording started and the baseline phase was completed. Participants then completed a 5-minute resting-state recording with their eyes closed. Then, participants underwent placebo acquisition and evocation. Subsequently, participants completed a second 5-minute resting-state recording. After the end of the experiment, participants completed the

exit questionnaire. Finally, a debriefing was conducted and participants were reimbursed for their participation.

### *Data handling*

Analyses of behavioral data were performed for descriptive purposes and to confirm that a significant placebo effect was induced. Next, specific hypotheses were tested, starting with resting-state EEG data. For all hypotheses, we looked at the frequency bands of interest (alpha, beta, and gamma) and two EEG parameters of interest (oscillatory power and Detrended Fluctuation Analysis). Our primary hypothesis was that there would be pre- to post-acquisition decreases in LRTC in the alpha band, given the role of alpha oscillations in pain processing as well as previous findings regarding the role of oscillatory complexity in cognitive functions. To test this, we assessed how placebo acquisition affected EEG parameters during rest by examining differences from before to after placebo acquisition. We then examined whether direct links could be observed between placebo-induced changes in resting-state brain activity (pre- to post-acquisition) and the magnitude of induced placebo hyperalgesia, with the aim to identify resting-state biomarkers of placebo hyperalgesia. For this purpose, we correlated any pre- to post-acquisition changes in EEG parameters with the magnitude of reported placebo hyperalgesia. We then examined EEG parameters during the experience of pain stimulations. We first asked whether the experience of control and placebo trials during the acquisition and evocation phases would be characterized by divergent EEG biomarker values. We then focused on potential differences in brain activity during the experience of high pain at baseline and the experience of heightened pain under placebo hyperalgesic conditions (i.e., when lower pain stimulation is perceived as high pain, during placebo evocation). We thus compared the experience of baseline high-pain stimulations and placebo-

augmented pain to establish whether they are characterized by divergent EEG biomarker values. Finally, we explored the correlation between pain-related psychological questionnaires and measures of EEG.

### *Nocebo manipulation check*

The magnitude of reported nocebo hyperalgesia was measured within-subjects, and was defined as the difference in pain ratings for the first nocebo trial compared to the first control trial, during evocation. The first evocation trials were selected to answer the manipulation-check question of whether significant nocebo hyperalgesia was induced, as previous studies indicate the effect to be clearest in those trials<sup>31,32</sup>.

### *Behavioral data handling*

Behavioral data were analyzed by use of SPSS 23.0 (IBM Corp., Armonk, NY, USA). The threshold for significance was set at  $P < 0.05$  and partial eta-squared ( $\eta_p^2$ ) was computed as a measure of effect size, with  $\eta_p^2$  of 0.01 considered small, 0.06 considered medium, and 0.14 considered a large effect size<sup>33,34</sup>. To conduct repeated measures analysis of variance (ANOVA), the assumptions of normality and homogeneity of variances were checked.

### *Computation of EEG biomarkers*

Spectral and temporal biomarkers were computed for all EEG recordings within three canonical frequency bands: alpha (8–13 Hz),

beta (13–30 Hz) and gamma (30–45 Hz). To quantify local neural dynamics associated with resting-state brain activity and pain responses in our nocebo paradigm, spectral power was computed for all EEG electrodes using the *Welch* method implemented in Matlab. Relative power was computed as the relative contribution of power within a narrow band to the integrated power within the range 1–45 Hz. To investigate whether temporal structure of the EEG changed at rest and during pain responses in our nocebo paradigm, the amplitude envelope was extracted using the Hilbert transform and DFA was computed to quantify LRTC of neuronal oscillations<sup>20–22</sup>. DFA quantifies the rate at which auto-correlations of amplitude modulations decay within a signal, with the power-law exponent ranging from 0.5 (uncorrelated) to 1.0 (strong auto-correlations). Signals were filtered using a FIR-filter with a Hamming window with a length corresponding to two  $f_i$  Hz cycles for a given frequency band  $[f_1, f_2]$ . To minimize artificial auto-correlations introduced by the FIR-filter, DFA was fitted in the interval from 4 to 20 seconds for alpha band and 2 to 20 secs for beta and gamma bands<sup>20</sup>.

### *EEG processing*

MATLAB 2020a (The MathWorks Inc., Natick, MA, 2014) was used for EEG preprocessing and analysis. Continuous EEG recordings were imported and preprocessed using EEGLAB<sup>35</sup>, and analyzed using custom-made scripts from a MATLAB toolbox developed at Vrije Universiteit Amsterdam (VU). All signals were visually inspected for artifacts in windows of 10 seconds. Noisy channels (e.g., with no or bad conductance to the scalp) and segments containing transient artifacts were removed. Next, recordings were re-referenced to the average BioSemi reference. Independent Component Analysis (ICA) was used to project signals to components that are maximally independent from each other<sup>36,37</sup>. Eye components were rejected. Continuous EEG

recordings were segmented into conditions by pasting together all epochs of a single condition. Segmentation was done using markers of the following conditions: baseline moderate-pain stimulations (10 seconds each), baseline high-pain stimulations (10 seconds each), first eyes-closed rest (ECR1; 5 minutes), control acquisition stimulus (10 seconds each), placebo acquisition stimulus (10 seconds each), control evocation stimulus (10 seconds each), placebo evocation stimulus (10 seconds each), and second eyes-closed rest (ECR2; 5 minutes). Exclusion of certain segments (for example, segments that were too short for DFA computation) resulted in a varying number of participants across analyses and figures.


### *Statistical analysis*

EEG biomarkers were computed and tested per EEG-channel for all 32 channels. Non-parametric paired Wilcoxon signed-rank test was used to test for differences between each two conditions. Multiple-comparison corrections were performed using a False Discovery Rate procedure (FDR) with  $q = 0.05$  <sup>35,36</sup>. For the Wilcoxon signed-rank test, we reported the median of the two conditions tested, the  $Z$ -value and the  $P$ -value. To test for associations between EEG biomarkers and behavioral outcome measures, we calculated Spearman's rank correlation coefficient ( $r_s$ ). On all spatial topographies, open white circles reflect statistical significance at  $P < 0.05$ , whereas closed white circles indicate statistical significance after FDR correction. Since some statistical effects were widespread across the cortex and others were localized above specific brain areas, we report statistics of the whole-brain average and additionally report statistics of specific electrodes in case of localized effects.

## ***Results***

### ***Participants and pain reports***

Thirty-nine participants were enrolled in this study and underwent calibration, conditioning, and evocation of nocebo hyperalgesia (**Fig. 1a, b**). Testing of three participants was discontinued: one due to technical difficulties, one for experiencing discomfort and headache during testing, and one for not reporting differences in experienced pain between acquisition control and nocebo trials. A total of 36 participants (25 female) were included in final analyses. Mean warmth detection threshold across participants was 33.7°C (standard deviation; SD = 0.7) and mean pain threshold was 41.9°C (SD = 3.2). Mean temperatures used to induce moderate and high pain were 46.6°C (SD = 0.8) and 48.1°C (SD = 0.5), respectively. At baseline, mean NRS pain rating for control trials was 4.4 (SD = 1.7), while mean pain rating for nocebo trials was 7.4 (SD = 1.2). During nocebo acquisition, mean pain rating for control trials was 3.9 (SD = 1.8) and mean pain rating for nocebo trials was 7.3 (SD = 1.4). Conditioning of pain during the acquisition phase successfully induced negative associations with the gel and evoked nocebo responses during evocation (**Fig. 1c**). A repeated measures ANOVA was conducted with trial type as within-subjects factor with two levels (first evocation nocebo trial, first evocation control trial), to establish whether significant nocebo hyperalgesia was induced. There was a significant difference between NRS reports for the first nocebo and first control trial of the evocation phase ( $F(1,35) = 27.44$ ,  $p = 0.000008$ ,  $\eta_p^2 = 0.44$ ) indicating the presence of nocebo hyperalgesia.




**Figure 1** - Experimental protocol and induced nocebo effect. **(a)** At the start of the recording, participants completed a first (PRE) resting-state, received (baseline) moderate and high pain stimulations, and underwent nocebo acquisition via conditioning and verbal suggestions, nocebo evocation, and a second (POST) resting-state. Blue and red fonts indicate the lower and higher pain conditions, respectively. ECR, Eyes-Closed Rest; PRE, Pre-acquisition; POST, Post-acquisition; TDA, Trans-Dermal Aspartate (sham hyperalgesic gel). Approximate pain in **1a** represents the moderate and high pain stimulations administered during acquisition and evocation, while **1c** represents reported pain during moderate pain in evocation. **(b)** Application sites where either no gel or sham hyperalgesic gel “TDA” was applied. **(c)** Manipulation-check results showing the pain ratings (and SD) for first nocebo and first control trials of the evocation phase for all participants ( $n = 36$ ).

***Pre- to post-acquisition changes in LRTC are negatively associated with the magnitude of induced nocebo hyperalgesia***

We asked whether differences in EEG due to nocebo conditioning were associated with magnitude of nocebo hyperalgesia (**Fig. 2**). Our primary hypothesis was that pre- to post-acquisition differences in the alpha band would be associated with magnitudes of induced nocebo hyperalgesia. There was no significant association between change in resting-state alpha power from pre- to post-acquisition and magnitude of nocebo hyperalgesia (mean across electrodes,  $r_s = -0.04$ ,  $p = 0.85$ ). We then looked more broadly at spectral and temporal biomarkers in alpha, beta and gamma bands to test for associations with the magnitude of nocebo hyperalgesia. Long-range temporal correlations were negatively associated with induced nocebo hyperalgesia for beta band for one lead (Electrode PO4,  $r_s = -0.43$ ,  $p = 0.02$ ) (**Fig. 2b**), but not for alpha and gamma bands (**Fig. 2a, c**).

***LRTC of neuronal oscillations during rest predict pain response to nocebo treatment***

We then asked whether resting-state EEG parameters can predict magnitude of nocebo hyperalgesia. There was no association between DFA and magnitude of nocebo hyperalgesia within the alpha band ( $r_s = 0.25$ ,  $p = 0.18$ ; **Fig. 2d**). Nocebo hyperalgesia was significantly positively correlated with DFA of beta ( $r_s = 0.51$ ,  $p = 0.003$ ) (**Fig. 2e**) and gamma band ( $r_s = 0.47$ ,  $p = 0.008$ ) (**Fig. 2f**). These results show that individuals with strong LRTC during rest have a larger nocebo effect than individuals with weak LRTC. Since stronger LRTC reflect more complex neural dynamics, these findings indicate that people with more complex brain activity are more susceptible to the acquisition of nocebo.




**Figure 2.** Complexity of neuronal oscillations at baseline predicts pain response to placebo treatment. Spatial topographies show Spearman's rank correlation coefficient values ( $\rho$ ) of magnitude of placebo hyperalgesia and EEG measures ( $n = 33$ ). Magnitude of placebo hyperalgesia was defined as the difference between mean pain response of all placebo trials and all control trials during the evocation phase, per individual. Top row shows the association between magnitude of placebo hyperalgesia and EEG parameters for the difference condition  $ECR_{POST} - ECR_{PRE}$ . Bottom row shows the correlation of placebo hyperalgesia with EEG condition  $ECR_{PRE}$ . (a-c) Magnitude of placebo hyperalgesia was negatively associated with DFA within beta and gamma bands. (d-f) Individuals with high DFA beta and gamma at baseline ( $ECR_{PRE}$ ) show a larger placebo effect during evocation. Red colors indicate positive correlations, whereas blue colors indicate negative correlations. Open white circles show statistical significance at  $P < .05$ . Closed white circles indicate significance after correcting for multiple comparisons using a False Discovery Rate procedure (FDR) with  $q = 0.05$ , per topography.

### *Nocebo conditioning suppresses power of alpha and beta oscillations*

Next, we assessed whether parameters of resting-state EEG are altered during placebo acquisition. To this end, non-parametric paired Wilcoxon signed-rank tests were conducted to compare differences in power and DFA between placebo and control trials during the induction phase of the study (Fig. 3a-c; Table 1). Relative power of alpha oscillations was significantly lower during placebo compared to control trials, in particular above parietal and occipital regions (Electrode PO3,  $Z = 2.73$ ,  $p = 0.0064$ ) (Fig. 3d). Relative power beta was significantly lower during placebo than during control trials above central regions (Electrode Cz,

$Z = 3.05, p = 0.0023$ ) (**Fig. 3e**). There were no significant differences in relative power gamma between nocebo and control trials after multiple comparisons correction ( $Z = -1.53, p = 0.13$ ) (**Fig. 3f, g**). There were no significant differences in LRTC between nocebo and control trials within alpha ( $Z = -0.35, p = 0.73$ ), beta ( $Z = -0.79, p = 0.43$ ) and gamma bands ( $Z = -1.43, p = 0.15$ ) after multiple comparisons correction (**Fig. 3h-k**). We then asked whether neurophysiological changes in spectral power were also observed during the evocation phase of the study. No significant differences were observed between nocebo and control trials in the evocation phase (**supplementary material**).



**Figure 3.** Oscillatory power of alpha and beta oscillations is suppressed during conditioning of nocebo hyperalgesia. (a) An EEG signal consists of brain oscillations with

power varying across frequency. Long-range temporal correlations were quantified using Detrended Fluctuation Analysis (DFA), which measures autocorrelations within a signal over time. **(b)** Power spectral density (PSD) was computed using Welch's method with a Hamming window and a frequency resolution of 0.125 Hz. Frequency bands were defined as alpha (8–13 Hz), beta (13–30 Hz) and gamma (30–45 Hz). **(c)** Mean PSD of control (grey line,  $n = 34$ ) and placebo trials (blue line,  $n = 34$ ) plotted in log-log scale. Wilcoxon signed-rank test was used to test for statistical significance between control and placebo trials, per frequency bin. Black bars indicate frequency bins with  $P < .05$ . Shaded areas indicate standard error of the mean. **(d-f)** Difference in relative power alpha (d), beta (e) and gamma band (f) for placebo minus control trials, mean of all subjects. Open white circles show statistical significance at  $P < .05$ . Closed white circles indicate significance after correcting for multiple comparisons (FDR) with  $q = 0.05$ , per topography. **(g)** Boxplots for relative power alpha. **(h-j)** Difference in DFA (h), beta (i) and gamma band (j) for placebo minus control, mean of all subjects. **(k)** Boxplots for DFA.


### ***LRTC and alpha power differentiate placebo pain from pain at baseline***

Our next question was whether these differences in and associations with LRTC of beta and gamma oscillations were present only during rest or if they also reflected placebo hyperalgesia. To this end, Wilcoxon signed-rank tests were used to compare power and DFA of high pain at baseline EEG measurement with placebo trials during the evocation phase. **(Fig. 4, Table 2)**. Compared to baseline high pain, relative power within the alpha band was significantly higher during placebo pain ( $Z = -3.5, p = 0.0004$ ) **(Fig. 4a)**. Relative power of gamma oscillations was lower during placebo pain than during baseline high pain ( $Z = 3.3, p = 0.001$ ) **(Fig. 4c)**. Relative power within the beta band was not significantly different between placebo during evocation and baseline high pain ( $Z = 0.5, p = 0.61$ ) **(Fig. 4b)**. DFA was higher during placebo pain than during baseline high pain for alpha oscillations above frontal and parietal regions, however, not significant after FDR-correction and not significant for the whole-brain average ( $Z = -1.31, p = 0.19$ ) **(Fig. 4g)**. DFA was lower during placebo pain than during baseline high pain for beta ( $Z = 3.14, p = 0.002$ ) and gamma band ( $Z = 3.76, p = 0.0002$ ) **(Fig. 4h-i)**. These results indicate that power within the alpha band was

higher during nocebo pain compared to baseline high pain. Interestingly, gamma power and LRTC were lower, suggesting that complexity of neuronal oscillations is lower, during nocebo-augmented pain compared to high pain at baseline. Indeed, based also on the results above, the complexity of neuronal oscillations seems to increase, from resting-state, to nocebo-augmented pain, to high administered pain.

*No significant relationship between questionnaire scores and EEG biomarkers*

Finally, we expected that there would be a relationship between scores on pain-related questionnaires and measures of EEG. Spearman's rank order correlations were conducted between total scores on each of the questionnaires (FPQ, PCS, and ECIP) and changes in resting-state EEG biomarker values from before to after nocebo induction. After correcting for multiple comparisons, no significant correlations were found between questionnaire scores and any of the biomarker values in any clusters of electrodes (**supplementary material**).



**Figure 4.** LRTC of beta and gamma oscillations differentiate nocebo pain from high pain at baseline. Spatial topographies show the mean difference NoceboEvocation - BaselineHighPain for all subjects ( $n = 33$ ; **a-d**) Relative power of alpha oscillations was significantly higher, whereas relative power of gamma oscillations was significantly lower, during nocebo pain, compared to high pain at baseline. (**e-h**) DFA of alpha oscillations was significantly higher above frontal and parietal areas. DFA of beta and gamma oscillations – in particular above frontal regions – was significantly lower during nocebo pain compared to high pain at baseline. Open white circles show statistical significance at  $P < .05$ . Closed white circles indicate significance after correcting for multiple comparisons (FDR) with  $q = 0.05$ , per topography. All boxplots show the mean across all electrodes.

**Table 1.** Summary of statistics for differences in EEG parameters (nocebo/control) conditioning (Figure 2).

| EEG parameter        | Electrode | Mdn <sub>CONT</sub> | Mdn <sub>NOC</sub>  | Z           | p             |
|----------------------|-----------|---------------------|---------------------|-------------|---------------|
| Relative power alpha | WBA       | 17.2 ± 1.77         | 17.04 ± 1.58        | 1.75        | 0.08          |
|                      | PO3       | <b>24.88 ± 2.36</b> | <b>19.53 ± 2.12</b> | <b>2.73</b> | <b>0.0064</b> |
| Relative power beta  | WBA       | 17.86 ± 1.13        | 18.55 ± 1.07        | -0.20       | 0.84          |
|                      | Cz        | <b>15.42 ± 1.60</b> | <b>14.6 ± 1.56</b>  | <b>3.05</b> | <b>0.0023</b> |
| Relative power gamma | WBA       | 6.99 ± 0.75         | 7.33 ± 0.70         | -1.53       | 0.13          |
| DFA alpha            | WBA       | 0.69 ± 0.01         | 0.68 ± 0.01         | -0.35       | 0.73          |
| DFA beta             | WBA       | 0.68 ± 0.01         | 0.69 ± 0.01         | -0.79       | 0.43          |
| DFA gamma            | WBA       | 0.69 ± 0.01         | 0.69 ± 0.01         | -1.43       | 0.15          |

*Note:* Rows show EEG parameters, columns show the median whole-brain average value across subjects for control and nocebo trials, Z- and P-value corresponding to the signed-rank test. The median EEG parameter value for each group is reported with the SE.

**Table 2.** Summary of statistics for differences in EEG parameters between placebo during evocation and baseline high pain shown in Figure 4.

| EEG parameter        | Electrode | Mdn <sub>BHP</sub>  | Mdn <sub>NOC</sub>  | Z            | p             |
|----------------------|-----------|---------------------|---------------------|--------------|---------------|
| Relative power alpha | WBA       | <b>13.91 ± 1.84</b> | <b>19.11 ± 1.72</b> | <b>-3.51</b> | <b>0.0005</b> |
| Relative power beta  | WBA       | 19.24 ± 1.19        | 17.83 ± 1.13        | 0.51         | 0.61          |
| Relative power gamma | WBA       | <b>9.37 ± 0.92</b>  | <b>5.96 ± 0.79</b>  | <b>3.28</b>  | <b>0.001</b>  |
| DFA alpha            | WBA       | 0.68 ± 0.01         | 0.69 ± 0.01         | -1.31        | 0.19          |
| DFA beta             | WBA       | <b>0.73 ± 0.01</b>  | <b>0.68 ± 0.01</b>  | <b>3.14</b>  | <b>0.0017</b> |
| DFA gamma            | WBA       | <b>0.81 ± 0.02</b>  | <b>0.72 ± 0.01</b>  | <b>3.76</b>  | <b>0.0002</b> |

*Note:* Wilcoxon signed-rank tests were performed on the whole-brain average per subject (computed as mean of all electrodes). Rows show EEG parameters, columns show the median whole-brain average value across subjects for control and placebo trials, Z- and P-value corresponding to the signed-rank test. The median EEG parameter value for each group is reported with the standard error of the mean. BHP: Baseline high pain, NOC: Nocebo trials during evocation. Bold font weight indicates significance at  $P < 0.05$ .

## Discussion

This study provides a novel characterization of the electrophysiological phenotype of placebo hyperalgesia using EEG. Spectral and temporal dynamics of brain oscillations were studied at baseline, during resting-state pre- and post- measurements and during placebo acquisition and evocation. The main findings of this study are (i) a negative correlation between LRTC of beta oscillations and the magnitude of placebo hyperalgesia, (ii) a positive correlation between baseline LRTC and magnitude of placebo hyperalgesia, (iii) alpha and beta power suppression during placebo conditioning, and (iv) biomarker differences between the experience of high pain at baseline and the experience of placebo-augmented pain.

In previous research, reduction in LRTC of oscillations has been reported in the alpha and beta bands in patients with cognitive disorders <sup>23,24,38</sup>, while other studies link increased LRTC to reduced attention or cognitive performance <sup>22,39–42</sup>. LRTC characterize neuronal systems that require rapid reorganization and responsiveness to changing processing demands <sup>25</sup>. Previous research indicates that neuronal systems involved in sustained attention may be characterized by a less volatile state with decreased LRTC <sup>25</sup>. LRTC changes in the present study may thus be related to reduced attention or cognitive performance. In other words, effective conditioning required sustained attention with a relatively low cognitive load to result in stronger learning and thus larger nocebo hyperalgesia was characterized by reduced complexity of neural dynamics.

While on one hand sustained attention (characterized by decreased LRTC) was related to larger nocebo responses, on the other hand strong resting-state LRTC at baseline predict more effective conditioning of nocebo responses. We found that, during rest, before the start of the experimental phases, strong LRTC predicted higher nocebo responses. This finding relates to the above-mentioned studies, that pointed towards an involvement of LRTC in cognitive ability <sup>23,24,38</sup>. Stronger LRTC reflect more complex neural dynamics and therefore, it appears that people with more complex baseline brain activity may exhibit higher cognitive functioning (Montez et al., 2009) and are thus more susceptible to the acquisition of nocebo hyperalgesia through learning. Here, the implication of gamma band oscillations is in line with EEG research on (associative) learning, suggesting that memory encoding involves gamma oscillations <sup>12,43,44</sup> potentially in coordination with hippocampal function <sup>45</sup>. This links gamma oscillations, which were shown to be involved in nocebo in this study, to a role of the hippocampus in learning and nocebo hyperalgesia <sup>46,47</sup>. It is also noteworthy that emotional processes that may play a mediating role in nocebo hyperalgesia, such as fear <sup>48</sup>, may engage patterns of gamma coupling in the amygdala <sup>49</sup>, a structure

that has also been implicated in nocebo hyperalgesia <sup>47,50,51</sup>. Our finding of increased complexity of gamma-band oscillations in those more susceptible to nocebo hyperalgesia may thus provide electrophysiological evidence of specific underlying cognitive-emotional processes, such as associative learning ability as well as fear processing.

Alpha band oscillatory power has been shown to underlie the perceptual processing of incoming stimuli, including sensory perception <sup>52</sup>. Our study was methodologically different from the two previous studies on electrophysiological nocebo correlates <sup>15,18</sup> and our results do not show consistent support of previous findings relating alpha oscillations to nocebo hyperalgesia. While our findings indicate an involvement of alpha band oscillations during acquisition, we did not find pre- to post-acquisition changes in alpha oscillations. Methodologically, it is possible that the time elapsed between the first and second resting state recordings was too long, resulting in a failure to capture electrophysiological changes in alpha oscillations related to nocebo processing.

Nevertheless, we found that nocebo trials during the acquisition phase were characterized by decreased power in the alpha band, as compared to control trials. Our finding may reflect the formation of pain expectations and an inhibitory function of alpha oscillations in pain perception. Moreover, alpha-band oscillations were involved when comparing the experience of baseline high-pain stimulations to the experience of increased pain under nocebo hyperalgesic conditions, in the evocation phase. We found that there was a significant increase in alpha-band power during nocebo responses, compared to baseline pain of a matched, high intensity pain stimulus. In line with the literature, these findings may reflect the role of alpha-band oscillations in expectations <sup>8,9</sup>, and the cognitive regulation of pain <sup>10,11</sup>.

We then aimed to differentiate the temporal electrophysiological profile of experiencing high pain at baseline from that of experiencing high pain as a result of induced placebo hyperalgesia. We found that the complexity of neuronal oscillations was lower during placebo-augmented pain compared to baseline pain of a matched, high intensity pain stimulus. Lower oscillatory complexity during placebo-augmented pain may be in line with our finding that lower LRTC during acquisition were associated with higher placebo magnitudes. This could mean that the evocation of placebo hyperalgesia, due to a state of sustained attention, may be characterized by decreased LRTC<sup>22,39–42</sup>. Placebo-augmented pain seems to rely on cognitive processes such as learning, memory recall, and pain modulation. Decreased LRTC may thus indicate increased attentional load or cognitive performance during placebo-augmented pain responses. More specifically, the decreased LRTC of gamma oscillations during placebo evocation, as compared to the baseline high pain, may alternatively or additionally indicate a learning process. It has previously been shown that while learning new information may lead to increased gamma power or synchronization<sup>43,45,53</sup>, power of gamma oscillations may show a decrease after learning<sup>54</sup>. It is thus possible that in placebo evocation, when learning is discontinued, gamma oscillations exhibit a decrease in power that reflects a previous active learning state. These results may thus highlight pronounced cognitive and learning-related differences between the neurophysiology of experiencing high pain and experiencing placebo-evoked increased pain. Nevertheless, the LRTC findings in this study also highlight the intricacy of such complex biomarkers of temporal brain function and how they may characterize diverse cognitive functions and loads in different ways.

A number of limitations may have impacted the results of this study. First, aggregating trials of specific conditions into 10-second segments may have smeared out effects that could have been better captured using an event-related paradigm, in which the exact onset of each pain

stimulus or response could be used to epoch the data into segments locked to each trial. Furthermore, the generalizability of our findings may be limited by the recruitment of a healthy, young participant sample. Findings of this study may not be consistent with results derived from pain patients or individuals who have experienced severe or chronic pain in the past, as their electrophysiological phenotype may differ from that of healthy people <sup>55</sup>.

With a number of novel aspects of the neurophysiological phenotype of nocebo hyperalgesia emerging through the present study, future directions are also coming into view. It is imperative for future research to focus on the generalizability and translation of experimental results into clinical practice. This study highlighted novel EEG biomarkers that are related to the experimental nocebo context. EEG is a practical and relatively cost-effective method that may provide a valuable means for the identification of nocebo-augmented pain as well as nocebo contexts. For these diagnostic potentials to be realized, a next step is for future studies to replicate our findings in clinical contexts and populations.

In sum, the present study yielded a number of novel findings regarding the electrophysiology that may underlie or mediate nocebo hyperalgesia. We identified both spectral and temporal parameters that are related to nocebo-augmented pain, with the latter presenting as the most important correlate of nocebo hyperalgesia in this study. The role of learning and attention at the electrophysiological level was highlighted through the involvement of LRTC as well as the extensive involvement of gamma oscillations under hyperalgesic conditions. These results are an important step towards identifying physiological biomarkers of nocebo hyperalgesia, a phenomenon that, to date, does not have any formal diagnostic criteria. The identification of biomarkers of nocebo hyperalgesia may thus prove imperative in the strive to identify and treat these effects.

## References

1. Atlas, L. Y. & Wager, T. D. How expectations shape pain. *Neurosci. Lett.* **520**, 140–148 (2012).
2. Bräscher, A.-K., Becker, S., Desch, S., Kleinböhl, D. & Hölzl, R. Classically conditioned hyperalgesia-learning a nocebo response without verbal suggestion. *Eur. J. Pain Suppl.* **5**, 281 (2011).
3. Benedetti, F., Lanotte, M., Lopiano, L. & Colloca, L. When words are painful: Unraveling the mechanisms of the nocebo effect. *Neuroscience* **147**, 260–271 (2007).
4. Freeman, S. *et al.* Distinct neural representations of placebo and nocebo effects. *Neuroimage* **112**, 197–207 (2015).
5. Egsgaard, L. L. *et al.* Short-term cortical plasticity induced by conditioning pain modulation. *Exp. Brain Res.* **216**, 91–101 (2012).
6. Linkenkaer-Hansen, K. *et al.* Breakdown of long-range temporal correlations in theta oscillations in patients with major depressive disorder. *J. Neurosci.* **25**, (2005).
7. Martin, R. C., Gilliam, F. G., Kilgore, M., Faught, E. & Kuzniecky, R. Improved health care resource utilization following video-eeG-confirmed diagnosis of nonepileptic psychogenic seizures. *Seizure* **7**, 385–390 (1998).
8. Babiloni, C. *et al.* Anticipatory cortical responses during the expectancy of a predictable painful stimulation. A high-resolution electroencephalography study. *Eur. J. Neurosci.* **18**, 1692–1700 (2003).
9. Babiloni, C. *et al.* Expectancy of pain is influenced by motor preparation: A high-resolution EEG study of cortical alpha rhythms. *Behav. Neurosci.* **119**, 503–511 (2005).
10. Babiloni, C. *et al.* Attentional processes and cognitive performance during expectancy of painful galvanic stimulations: A high-resolution EEG study. *Behav. Brain Res.* **152**, 137–147 (2004).
11. Jensen, M. P., Gianas, A., Sherlin, L. H. & Howe, J. D. Pain Catastrophizing and EEG- $\alpha$  Asymmetry. *Clin. J. Pain* **31**, 852–8 (2015).
12. Miltner, W. H. R., Braun, C., Arnold, M., Witte, H. & Taub, E. Coherence of gamma-band EEG activity as a basis for associative learning. *Nature* **397**, 434–436 (1999).
13. Schulz, E. *et al.* Prefrontal Gamma Oscillations Encode Tonic Pain in Humans. (2015). doi:10.1093/cercor/bhv043
14. Tu, Y. *et al.* Alpha and gamma oscillation amplitudes synergistically predict the perception of forthcoming nociceptive stimuli. *Hum. Brain Mapp.* **37**, 501–514 (2016).
15. Albu, S. & Meagher, M. W. Expectation of nocebo hyperalgesia affects EEG alpha-activity. *Int. J. Psychophysiol.* **109**, 147–152 (2016).
16. Pazzaglia, C., Testani, E., Giordano, R., Padua, L. & Valeriani, M. Expectation to feel more pain disrupts the habituation of laser-pain rating and laser-evoked potential amplitudes. *Neuroscience* **333**, 244–251 (2016).
17. Piedimonte, A., Guerra, G., Vighetti, S. & Carlino, E. Measuring expectation of pain: Contingent negative variation in placebo and nocebo effects. *Eur. J. Pain* **21**, 874–885 (2017).
18. Tu, Y. *et al.* A neural mechanism of direct and observational conditioning for placebo and nocebo responses. *Neuroimage* (2019). doi:10.1016/j.neuroimage.2018.10.020

19. Hird, E. J., Jones, A. K. P., Talmi, D. & El-Deredy, W. A comparison between the neural correlates of laser and electric pain stimulation and their modulation by expectation. *J. Neurosci. Methods* **293**, 117–127 (2018).
20. Hardstone, R. *et al.* Detrended Fluctuation Analysis: A scale-free view on neuronal oscillations. *Front. Physiol.* **3**, 450 (2012).
21. Peng, C. K. *et al.* Mosaic organization of DNA nucleotides. *Phys. Rev. E* **49**, 1685–1689 (1994).
22. Linkenkaer-Hansen, K., Nikouline, V. V., Palva, J. M. & Ilmoniemi, R. J. Long-range temporal correlations and scaling behavior in human brain oscillations. *J. Neurosci.* **21**, (2001).
23. Nikulin, V. V., Jönsson, E. G. & Brismar, T. Attenuation of long-range temporal correlations in the amplitude dynamics of alpha and beta neuronal oscillations in patients with schizophrenia. *Neuroimage* **61**, 162–169 (2012).
24. Montez, T. *et al.* Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 1614–9 (2009).
25. Irmischer, M. *et al.* Controlling the Temporal Structure of Brain Oscillations by Focused Attention Meditation. *Hum. Brain Mapp.* **39**, 1825–1838 (2017).
26. Faul, F., Erdfelder, E. & Lang, A. G. G\*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav. Res. Methods* **39**, 175–191 (2007).
27. Rolke, R. *et al.* Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. *Pain* **123**, 231–243 (2006).
28. Sullivan, M.J.L., Bishop, S.R., Pivik, J. The Pain Catastrophizing Scale: Development and validation. *Psychol. Assess.* **7**, 524–532 (1995).
29. McNeil, D. W. & Rainwater, A. J. Development of the fear of pain questionnaire - III. *J. Behav. Med.* **21**, 389–410 (1998).
30. Attridge, N., Crombez, G., Van Ryckeghem, D., Keogh, E. & Eccleston, C. The Experience of Cognitive Intrusion of Pain: Scale development and validation. *Pain* **156**, 1978–1990 (2015).
31. Bartels, D. J. P. *et al.* Role of Conditioning and Verbal Suggestion in Placebo and Nocebo Effects on Itch. *PLoS One* **9**, e91727 (2014).
32. Colagiuri, B., Quinn, V. F. & Colloca, L. Nocebo Hyperalgesia, Partial Reinforcement, and Extinction. *J. Pain* **16**, 995–1004 (2015).
33. Richardson, J. T. E. Eta squared and partial eta squared as measures of effect size in educational research. *Educ. Res. Rev.* **6**, 135–147 (2011).
34. Cohen, J. A power primer. *Psychol. Bull.* **112**, 155–159 (1992).
35. Delorme, A. & Makeig, S. EEGLAB: An open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. *J. Neurosci. Methods* **134**, 9–21 (2004).
36. Bell, A. J. & Sejnowski, T. J. An information-maximization approach to blind separation and blind deconvolution. *Neural Comput.* **7**, 1129–1159 (1995).
37. Makeig, S., Jung, T.-P., Ghahremani, D. & Sejnowski, T. J. *Independent Component Analysis of Simulated ERP Data.* (1996).
38. Gao, F., Wu, X., Feng, Y. & Jia, H. Attenuation of temporal correlations of neuronal oscillations in patients with mild spastic diplegia. *Sci. Rep.* **7**, 1–11 (2017).
39. Deco, G., Jirsa, V. K. & McIntosh, A. R. Resting brains never rest: Computational insights into potential cognitive architectures. *Trends in Neurosciences* **36**, 268–274 (2013).

40. Singer, W. Cortical dynamics revisited. *Trends in Cognitive Sciences* **17**, 616–626 (2013).
41. Poil, S.-S., Hardstone, R., Mansvelder, H. D. & Linkenkaer-Hansen, K. Critical-State Dynamics of Avalanches and Oscillations Jointly Emerge from Balanced Excitation/Inhibition in Neuronal Networks. *J. Neurosci.* **32**, (2012).
42. Irmischer, M., Poil, S. S., Mansvelder, H. D., Intra, F. S. & Linkenkaer-Hansen, K. Strong long-range temporal correlations of beta/gamma oscillations are associated with poor sustained visual attention performance. *Eur. J. Neurosci.* **48**, 2674–2683 (2018).
43. Tort, A. B. L., Komorowski, R. W., Manns, J. R., Kopell, N. J. & Eichenbaum, H. Theta-gamma coupling increases during the learning of item-context associations. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 20942–20947 (2009).
44. McNally, J. M., McCarley, R. W. & Brown, R. E. Chronic ketamine reduces the peak frequency of gamma oscillations in mouse prefrontal cortex ex vivo. *Front. Psychiatry* **4**, (2013).
45. Jutras, M. J., Fries, P. & Buffalo, E. A. Gamma-band synchronization in the macaque hippocampus and memory formation. *J. Neurosci.* **29**, 12521–12531 (2009).
46. Kong, J. *et al.* A Functional Magnetic Resonance Imaging Study on the Neural Mechanisms of Hyperalgesic Nocebo Effect. *J. Neurosci.* **28**, 13354–13362 (2008).
47. Jensen, K. *et al.* A neural mechanism for nonconscious activation of conditioned placebo and nocebo responses. *Cereb. Cortex* **25**, 3903–3910 (2015).
48. Thomaidou, M. A., Veldhuijzen, D. S., Meulders, A. & Evers, A. W. M. An experimental investigation into the mediating role of pain-related fear in boosting nocebo hyperalgesia. *PAIN®* **162**, 287–299 (2021).
49. Stujenske, J. M., Likhtik, E., Topiwala, M. A. & Gordon, J. A. Fear and Safety Engage Competing Patterns of Theta-Gamma Coupling in the Basolateral Amygdala. *Neuron* **83**, 919–933 (2014).
50. Schmid, J. *et al.* Neural underpinnings of nocebo hyperalgesia in visceral pain: A fMRI study in healthy volunteers. *Neuroimage* **120**, 114–122 (2015).
51. Tinnermann, A., Geuter, S., Sprenger, C., Finsterbusch, J. & Büchel, C. Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia. *Science (80- )* **358**, 105–108 (2017).
52. Forschack, N., Nierhaus, T., Müller, M. M. & Villringer, A. Alpha-Band Brain Oscillations Shape the Processing of Perceptible as well as Imperceptible Somatosensory Stimuli during Selective Attention. *J. Neurosci.* **37**, 6983–6994 (2017).
53. Luo, W. & Guan, J.-S. Do Brain Oscillations Orchestrate Memory? *Brain Sci. Adv.* **4**, 16–33 (2018).
54. Madhavan, R. *et al.* Decrease in gamma-band activity tracks sequence learning. *Front. Syst. Neurosci.* **8**, 222 (2015).
55. Pinheiro, E. S. dos S. *et al.* Electroencephalographic Patterns in Chronic Pain: A Systematic Review of the Literature. *PLoS One* **11**, e0149085 (2016).